PowerShares Dynamic Pharmaceuticals ETF

Latest PowerShares Dynamic Pharmaceuticals ETF News and Updates

  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

    By Margaret Patrick
  • uploads///Van Eck Video
    Macroeconomic Analysis

    What Are Generic Drugs and Why Are They Important?

    TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]

    By VanEck
  • uploads///Chart  EPS
    Miscellaneous

    Understanding Allergan’s Valuation after the 1Q17 Results

    On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.

    By Mike Benson
  • uploads///Immunology Oncology
    Company & Industry Overviews

    A Look into Merck’s Immunology and Oncology Portfolio

    In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

    By Daniel Collins
  • uploads///Eliquis and Sprycel
    Company & Industry Overviews

    Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

    In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

    By Daniel Collins
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///portfolio
    Company & Industry Overviews

    Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst

    Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

    By Jillian Dabney
  • uploads///novartis
    Fund Managers

    Maverick Capital Increases Stake in Novartis

    Maverick Capital increased its position in Novartis (NVS) by more than $22 million in stock. It represented 0.75% of the fund’s total portfolio in 4Q14.

    By Patricia Garner
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • Financials

    Overview: New York Fed’s advice to revive Puerto Rico’s economy

    In 2011, led by Dr. William Dudley, the New York Fed had commissioned a report on the major economic issues facing the island of Puerto Rico.

    By Phalguni Soni
  • uploads///bausch
    Company & Industry Overviews

    How Bausch Health’s Financials Look in November

    Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

    By Daniel Collins
  • uploads///Januvia
    Company & Industry Overviews

    A Look at Merck’s Diabetes and Women’s Health Business

    Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.

    By Daniel Collins
  • uploads///Chart
    Healthcare

    How Did Pharmaceutical ETFs Perform in Q3 2018?

    The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s SpotLyte and Lumivive System

    SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Eli Lilly’s Valuation as of September 27?

    Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.

    By Mike Benson
  • uploads///MJ Acceptance
    Company & Industry Overviews

    Vermont Legalizes Recreational Marijuana on January 22, 2018

    On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.

    By Adam Jones
  • uploads///Branded Rx prod
    Company & Industry Overviews

    Behind Valeant’s Branded Drugs: Other 3Q17 Performances

    In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.

    By Daniel Collins
  • uploads///Jazz analyst
    Company & Industry Overviews

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

    By Daniel Collins
  • uploads///Siliq
    Company & Industry Overviews

    Valeant Pharmaceuticals’ Siliq Approved for Plaque Psoriasis

    In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals’ (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.

    By Daniel Collins
  • uploads///LEP
    Company & Industry Overviews

    How Pfizer’s Premarin and Other Legacy Established Products Performed

    In 3Q17, Pfizer’s (PFE) Premarin generated revenues of $238 million, a ~2% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  Keytruda Revenues
    Company & Industry Overviews

    Keytruda: Driving Merck’s Growth

    For 3Q17, Keytruda reported revenues of ~$1.1 billion, a 194% growth compared to revenues of $356 million in 3Q16.

    By Mike Benson
  • uploads///Chart  Oncology
    Company & Industry Overviews

    Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17

    In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.

    By Mike Benson
  • uploads///Remicade
    Company & Industry Overviews

    Merck’s Immunology and Oncology Drugs, Post-3Q17

    Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]

    By Daniel Collins
  • uploads///
    Macroeconomic Analysis

    What Led to the Rise in the US Trade Deficit in September?

    The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.

    By Ricky Cove
  • uploads///Chart  Eliquis
    Company & Industry Overviews

    Bristol-Myers Squibb’s Cardiovascular Portfolio

    Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis, developed in alliance with Pfizer (PFE).

    By Mike Benson
  • uploads///Chart  Diabetes
    Company & Industry Overviews

    How Merck’s Diabetes Portfolio Performed in 2Q17

    Merck’s (MRK) diabetes portfolio includes drugs used for controlling the blood sugar levels for patients with diabetes.

    By Mike Benson
  • uploads///Vyxeos
    Company & Industry Overviews

    Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018

    In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.

    By Daniel Collins
  • uploads///Chart  Development
    Company & Industry Overviews

    Eli Lilly & Co.’s Recent Developments after Its 2Q17 Earnings

    On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.

    By Mike Benson
  • uploads///Chart  Endo
    Company & Industry Overviews

    Performance of Eli Lilly’s Endocrine Franchise in 2Q17

    Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.

    By Mike Benson
  • uploads///II
    Company & Industry Overviews

    How Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17

    In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.

    By Daniel Collins
  • uploads///IM
    Company & Industry Overviews

    A Post-2Q17 Look at Pfizer’s Internal Medicines

    In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  Orencia
    Company & Industry Overviews

    Bristol-Myers Squibb’s Immunoscience Products in 2Q17

    Orencia revenues rose to $650.0 million in 2Q17, a 10.0% rise compared to $593 million in 2Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Jazz Pharmaceuticals Expects for Vyxeos

    If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.

    By Margaret Patrick
  • uploads///Chart  USST
    Company & Industry Overviews

    How Allergan’s US Specialized Therapeutics Segment Performed in 2Q17

    The US Specialized Therapeutics segment reported revenues of $1.7 billion in 2Q17, a 15.2% increase as compared to $1.5 billion during 2Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Behind Xyrem’s Solid Demand Trends in 2017

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.

    By Margaret Patrick
  • uploads///Abraxane
    Company & Industry Overviews

    Celgene’s Abraxane Continued Steady Growth in 2Q17

    In 2Q17, Celgene’s (CELG) Abraxane generated revenues of around $254 million, which reflected ~2% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Dupixent Could Substantially Drive Regeneron’s Growth

    In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

    By Daniel Collins
  • uploads///Chart  Oncology
    Earnings Report

    Examining Bristol-Myers Squibb’s Oncology Portfolio’s 2Q17

    The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.

    By Mike Benson
  • uploads///Chart  Endo
    Earnings Report

    Eli Lilly in 2Q17: Humulin and Endocrine Products

    Eli Lilly’’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.

    By Mike Benson
  • uploads///LEP revenues
    Company & Industry Overviews

    Behind Pfizer’s Legacy Established Products Performance in 2017

    In 2016, Pfizer’s (PFE) Lipitor reported revenues of ~$1.8 billion, which represented a ~5% YoY (year-over-year) fall.

    By Daniel Collins
  • uploads///Chart  BS
    Company & Industry Overviews

    Behind Allergan’s Business Segments and Revenues

    Allergan’s (AGN) business has undergone several changes over the past few years due to acquisitions and divestitures.

    By Mike Benson
  • uploads///Chart  BMY
    Miscellaneous

    How Bristol-Myers Squibb Stock Has Performed in 2Q17

    A look at Bristol-Myers Squibb Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, immunoscience, oncology, and virology. Stock price performance While Bristol-Myers Squibb’s stock price has risen ~3.8% in 2Q17, it had fallen ~5.4% year-to-date as of July 7, […]

    By Mike Benson
  • uploads///Chart  Keytruda Revenues
    Company & Industry Overviews

    How Did Keytruda Perform in 1Q17?

    Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.

    By Mike Benson
  • uploads///Chart  Revenues
    Company & Industry Overviews

    A Look at Pfizer’s Revenue for 1Q17

    Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.

    By Mike Benson
  • uploads///Chart  EPS
    Company & Industry Overviews

    How Johnson & Johnson’s Valuation Changed Post-1Q17

    Heavyweight pharmaceutical company Johnson & Johnson (JNJ) reported earnings per share (or EPS) of $1.83 on revenue of $17.8 billion in 1Q17.

    By Mike Benson
  • uploads///Chart  JJ
    Company & Industry Overviews

    Performance of Merck’s Diabetes Portfolio in 1Q17

    Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  Virology
    Earnings Report

    Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment

    The Virology segment is Bristol-Myers Squibb’s (BMY) second-largest revenue contributor. The segment contributes ~25% of the company’s total revenue.

    By Mike Benson
  • uploads///Chart  Segment
    Earnings Report

    Johnson & Johnson’s 1Q17 Segment-by-Segment Performance

    JNJ’s overall business is classified into three segments: Pharmaceuticals, Consumer, and Medical Devices. At constant exchange rates, the company reported growth across all of its segments.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s 1Q17 Estimates: Pharmaceuticals Segment

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment includes immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics.

    By Mike Benson
  • uploads///Chart  ABT
    Miscellaneous

    Analyzing the Performance of Abbott Laboratories in 1Q17

    Abbott Laboratories’ stock price rose ~7.1% in 1Q17. On April 7, 2017, the stock’s price had risen 13.7% year-to-date (or YTD).

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Bausch & Lomb Continues to be Key Growth Driver for Valeant

    Bausch & Lomb projections Valeant Pharmaceuticals expects its Bausch & Lomb/International segment to grow at a CAGR (compound average growth rate) of 4%–6% between 2017 and 2020. In 2017, the company expects the segment to grow 5%–7% after adjusting for foreign exchange fluctuations and the impact of impending patent expiries. In 2017, the segment is also expected […]

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    New Product Launches May Boost Valeant’s Dermatology Revenue

    New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after 2018 through new product launches. On December 12, 2016, the company hired Bill Humpries as executive vice president and head of the dermatology team. The change […]

    By Margaret Patrick
  • uploads///Chart  Development
    Company & Industry Overviews

    Key Investor Insights into Eli Lilly’s Recent Developments

    Overall, Eli Lilly’s (LLY) segment-wise performance in 3Q16 was positive for both its Human Pharmaceuticals and Animal Health segments.

    By Mike Benson
  • uploads///A Region wise GNRX
    Company & Industry Overviews

    Why Generic Drugs Will Play a Key Role in the Future

    Although generic drugs are the same as branded drugs in terms of the medicinal effect, their prices are extremely low compared to the branded products.

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    Understanding Merck’s Business Segments and Their Revenue Trends

    Merck & Co. has separated its business operations into two business segments: the Global Human Health business and the Animal Health business.

    By Mike Benson
  • uploads///HCV drugs
    Company & Industry Overviews

    Population Dynamics for Gilead’s HCV Products

    There are six distinct genotypes of HCV (hepatitis C virus). If we know the genotype, recommending the treatment and duration becomes easier.

    By Jillian Dabney
  • uploads///danaher pall overview
    Company & Industry Overviews

    Pall Acquisition Gave Birth to Danaher’s Filtration Business

    Danaher’s filtration business came into existence through the acquisition of Pall in 2015.

    By Shannon Black
  • uploads///Chart  Segment
    Company & Industry Overviews

    How Are Eli Lilly’s Business Segments Performing?

    Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 2Q16 Estimates: Expect Growth!

    Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.

    By Mike Benson
  • uploads///API
    Company & Industry Overviews

    How Has Manufacturing Its Own Active Pharmaceutical Ingredients Helped Mylan?

    Mylan is one of largest API (active pharmaceutical ingredient) manufacturers in the world, with nine API and intermediate manufacturing facilities.

    By Seth Richards
  • uploads///Business Model
    Company & Industry Overviews

    Mylan’s Business Model: A Key Investor Rundown

    In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

    By Seth Richards
  • uploads///Chart
    Macroeconomic Analysis

    The PowerShares Dynamic Pharmaceuticals ETF: Holdings Breakdown

    As of November 2015, the PowerShares Dynamic Pharmaceuticals ETF (PJP) was one of the top-performing smart beta ETFs in the market.

    By Ivan Kading
  • uploads///Chart
    Macroeconomic Analysis

    Comparing the PowerShares Dynamic Biotechnology & Genome Portfolio with PJP

    PJP saw healthy growth in its volume and fund inflows compared to PBE as of November. Volumes traded per day grew in 2014 for PJP and PBE but fell in 2015.

    By Ivan Kading
  • uploads///Article
    Company & Industry Overviews

    Big pharma invests big money in research and development

    Research and development is likely the most vital part of big pharma. Out of every 10,000 drugs developed, barely 10 reach the market.

    By Mike Benson
  • Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.